Production and characterization of a recombinant chimeric antigen consisting botulinum neurotoxin serotypes A, B and E binding subdomains

Journal of Toxicological Sciences

Volumn 35, Issue 1, 2010, Pages 9-19

  Ebrahimi, Firouz ^a   Rasaee, Mohammad Javad ^a   Mousavi, Seyed Latif ^b   Babaeipour, Valiollah ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b SHAHED UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Botulinum neurotoxin; Chimeric protein; Vaccination

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; CHIMERIC PROTEIN; GANGLIOSIDIC RECEPTOR; RECEPTOR; RECOMBINANT ANTIGEN; SYNAPTOTAGMIN; SYNAPTOTAGMIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOTTING; CELL INCLUSION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; LD 50; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

MUS;

EID: 76749167117     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.35.9     Document Type: Article

References (27)

1. Arai, R., Ueda, H., Kitayama, A., Kamiya, N., and Nagamune, T. (2001): Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng., 14, 529-532.
2. Baldwin, M.R., Tepp, W.H. and Pier, C.L. (2005): Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect. Immun., 73, 6998-7005.
3. Brown, D.R., Lloyd, J.P. and Schmidt, J.J. (1997): Identification and characterization of a neutralizing monoclonal antibody against botulinum neurotoxin serotype F, following vaccination with active toxin. Hybridoma, 16, 447-456.
4. Byrne, M.P. and Smith, L.A. (2000): Development of vaccines for prevention of botulism. Biochimie, 82, 955-966.
5. Byrne, M.P., Smith, T.J., Montgomery, V.A. and Smith, L.A. (1998): Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun., 66, 4817-4822.
6. Clayton, M.A., Clayton, J.M., Brown, D.R. and Middlebrook, J.L. (1995): Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect. Immun., 63, 2738-2742.
7. de Paiva, A. and Dolly, J.O. (1990): Light chain of botulinum neurotoxin is active in mamalian motor nerve terminal when delivered via liposomes. FEBS Lett., 277, 171-174.
8. Dertzbaugh, M.T. and West, M.W. (1996): Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine, 14, 1538-1544.
9. Dong, A., Richards, D.A., Goodnough, M.C., Tepp, W.H., Gohnson, E.A. and Chapman, E.R. (2003): Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell Biol., 162, 1293-1303.
10. Kozaki, S. (1999): Studies on the receptor for Clostridium botulinum neurotoxin. Nippon Saikoqaku Zasshi, 54, 401-414.
11. Kozaki, S., Onimaru, J., Kamata, Y. and Sakaguchi, G. (1991): Immunological characterization of Clostridium butyricum neurotoxin and its trypsin-induced fragment by use of monoclonal antibodies against Clostridium botulinum type E neurotoxin. Infect. Immun., 59, 457- 459.
12. Lacy, D.B. and Stevens, R.C. (1999): Sequence homology and structural analysis of the clostridial neurotoxins. J. Mol. Biol., 291, 1091-1104.
13. Lalli, G., Herreros, J., Osborne, S.L., Montecucco, C., Rossetto, O. and Schiavo, G. (1999): Functional characterisation of tetanus and botulinum neurotoxins binding domains. J.Cell. Sci., 112, 2715-2724.
14. Li, L. and Singh, B.R. (1998): Isolation of synaptotagmin as a receptor for types A & identification of C-termini of light & heavy chain. J. Pro. Chem., 16, 787-799.
15. Li, L. and Singh, B.R. (1999): Structure -function relationship of clostridial neurotoxins. J. Toxicol., 18, 95-112.
16. Montecucco, C. and Schiavo, G. (1994): Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol., 13, 1-8.
17. Mousavi, M.L., Kouhsari, S.M., Nazarian, S., Rasooli, I. and Amani, J. (2004): Cloning, expression and purification of Clostridium botulinum neurotoxin type E binding domain. Iranian J. Biotech., 2, 183-188.
18. Nishiki, T., Kamata, Y., Nemoto, Y., Omori, A., Ito, T., Takahashi, M. and Kozaki, S. (1994): Identification of protein receptor for Clostridium botulinum Type B neurotoxin in rat brain synaptosomes. J. Biol. Chem., 269, 10498-10503.
19. Park, J.B. and Simpson, L.L. (2003): Inhalational poisoning by botulinum toxin and inhalation vaccination with heavy-chain component. Infect. Immun., 71, 1147-1154.
20. Rummel, A., Eichner, T., Weil, T., Karnath, T., Gutcaits, A., Mahrhold, S., Sandhoff, K., Proia, R.L. Acharya, K.R., Bigalke , H. and Binz, T. (2007): Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. PNAS, 104, 359-364.
21. Schiavo, G., Matteoli, M. and Montecucco, C. (2000): Neurotoxins affecting neuroexocytosis. Physiol. Rev., 80, 717-766.
22. Sharma, S., Zhou, Y. and Singh, B.R. (2005): Cloning, expression, and purification of C-terminal quarter of the heavy chain of botulinum neurotoxin type A. Protein Expr. Purit., 45, 288-295.
23. Shone, C.C. and Roberts, A.K. (1994): Peptide substrate specificity and properties in the zinc - endopeptidase activity of botulinum neurotoxin type B neurotoxin. Eur. J. Biochem., 225, 263-270.
24. Stephen, S.A., Robert, S., Thomas, V.I., Donald, A.H., John, G.B., Michael, S.A., Edward, E., Anne, D.F., Jerome, H., Marcelle, L., Scott, L., Michael, T.O., Tara, O., Gerald, P., Trish, M.P., Philip, K.R., David, L.S. and Kevin, T. (2001): Botulinum toxin as a biological weapon. JAMA, 285, 1059-1070.
25. Tavallaie, M., Chenal, A., Gillet, D., Pereira, Y., Manich, M., Gilbert, M., Raffestin, S., Popoff, M.R. and Marvaud, J.C. (2004): Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett., 572, 299-306.
26. Wictom, M. and Rossetto, O. (1996): Substrate residues N-terminal to the cleavage site of botulinum type B neurotoxin play a role in determining the specificity of its endopeptidase activity. FEBS Lett., 386, 133-136.
27. Zhou, Y. and Singh, B.R. (2004): Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain trans-membrane and binding domain. Protein Expr. Purif., 34, 8-16.